Late-Life Gene Therapy Extends Mouse Lifespan 20% by Boosting Metabolism
A single FGF21 gene injection in aging mice extended median lifespan by 20%, reversing fat gain, inflammation, and organ decline.
Summary
Researchers at the Autonomous University of Barcelona delivered a one-time gene therapy to aging mice that extended their median lifespan by over 20%. The treatment used a viral vector to make leg muscles continuously produce FGF21, a hormone that regulates energy metabolism. Starting in middle-aged mice, the therapy reversed weight gain without reducing food intake, improved glucose tolerance, boosted mitochondrial function, reduced inflammation, and protected the heart, kidneys, liver, and muscles from age-related damage. Cognitive performance and physical fitness also improved. These results suggest that sustained FGF21 elevation could mimic the benefits of caloric restriction and exercise, offering a potential therapeutic route to healthspan and lifespan extension in humans.
Detailed Summary
Metabolic decline is one of aging's earliest and most damaging processes. As we age, fat accumulates, insulin sensitivity drops, and cellular energy production becomes less efficient. Interventions like caloric restriction and exercise can slow this decline, but they're difficult to sustain long-term. This new study explores whether a one-time gene therapy can replicate those benefits permanently.
Researchers used an adeno-associated virus to deliver the FGF21 gene directly into leg muscles of 13-month-old male mice — roughly equivalent to middle age in humans. The treated muscles became permanent FGF21 factories, sustaining elevated hormone levels throughout the animals' lives. Remarkably, median lifespan jumped from 28 to 34 months, a 20.5% increase. A smaller group treated even later, at 22 months, also outlived untreated peers.
The health benefits were broad and striking. Treated mice lost weight back to youthful levels without eating less, indicating increased energy expenditure. Mitochondrial function improved significantly, with more mitochondria, better energy pathways, and preserved protein-synthesis capacity in muscles. Organs that typically deteriorate with age — liver, kidneys, heart, and skeletal muscle — showed dramatically reduced fibrosis, inflammation, and amyloid deposits compared to controls. Cognitive and physical fitness scores also improved.
From a practical standpoint, FGF21 gene therapy is already advancing toward human clinical trials via Kriya Therapeutics, targeting metabolic diseases like fatty liver and diabetes. This lifespan study adds weight to the therapeutic potential of FGF21 beyond metabolic disease alone, positioning it as a possible systemic aging intervention.
Important caveats apply. All subjects were male mice, so sex-specific and species-specific differences may limit direct translation to humans. The study does not yet clarify the precise molecular mechanisms driving lifespan extension versus healthspan improvements. Human trials will need to confirm safety and efficacy before this approach becomes clinically available.
Key Findings
- One-time FGF21 gene therapy in middle-aged male mice extended median lifespan by 20.5%, from 28 to 34 months.
- Treated mice lost weight to youthful levels without reducing food intake, driven by increased energy expenditure.
- Mitochondrial function, count, and protein-synthesis capacity were all significantly preserved in treated mice.
- Age-related organ damage — including fibrosis, amyloidosis, and inflammation in heart, liver, kidneys, and muscle — was largely absent in treated mice.
- Cognitive performance and physical fitness both improved, suggesting broad healthspan benefits beyond metabolic correction.
Methodology
This is a research summary reporting on a peer-reviewed study published in Molecular Therapy from the Autonomous University of Barcelona. The evidence basis is a controlled animal study using male mice with multiple longitudinal measurement points. Lifespan.io is a credible, science-focused longevity publication with a track record of accurately reporting primary research.
Study Limitations
The study was conducted exclusively in male mice, limiting applicability to females and humans without further research. Mechanisms underlying lifespan extension versus healthspan improvement are not fully resolved and warrant deeper investigation. Human translation depends on ongoing clinical trials confirming safety, optimal dosing, and long-term effects of sustained FGF21 elevation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.